Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTA) Non-Current Assets (2019 - 2025)

Strata Critical Medical (SRTA) has disclosed Non-Current Assets for 7 consecutive years, with $199.3 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 107.73% to $199.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $611.6 million through Dec 2025, up 55.48% year-over-year, with the annual reading at $199.3 million for FY2025, 107.73% up from the prior year.
  • Non-Current Assets for Q4 2025 was $199.3 million at Strata Critical Medical, down from $212.6 million in the prior quarter.
  • The five-year high for Non-Current Assets was $278.1 million in Q1 2021, with the low at $3.4 million in Q2 2021.
  • Average Non-Current Assets over 5 years is $103.7 million, with a median of $99.7 million recorded in 2022.
  • The sharpest move saw Non-Current Assets tumbled 98.77% in 2021, then surged 1243.92% in 2022.
  • Over 5 years, Non-Current Assets stood at $40.9 million in 2021, then skyrocketed by 161.12% to $106.9 million in 2022, then dropped by 17.05% to $88.7 million in 2023, then rose by 8.18% to $95.9 million in 2024, then skyrocketed by 107.73% to $199.3 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $199.3 million, $212.6 million, and $101.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.